AVOS Life Sciences

Table of Contents - Insomnia

Disease Etiology 5
Possible Causes of Insomnia 5
Insomnia Sub-Types 5
Primary Insomnia 5
Co-Morbid Insomnia 5
Epidemiology & Patient Population Estimates 6
Theoretical Patient Population 6
Addressable Patient Population 8
Treated Patient Population 8
Insomnia Patient Population Model 9
U.S. Insomnia Market, 2004-2013 10
Disease & Market Definitions 10
Forecasting Methodology 10
Market Revenue Forecasts 11
U.S. Insomnia Market Model, 2004-2013 13
AVOS Physician Panel Results 15
Physician Treatment Patterns 15
Patient Compliance 17
Non-Compliance Drivers 17
High Cost of Therapy 17
Negative Side Effects 17
Results Achieved Quickly 17
Delay in Achieving Desired Outcome 17
Physician Product Selection Criteria 18
Past Product Experience 18
Safety Profile 18
Patient Input 18
Availability of Samples 18
Long-Term Use 18
Cost of Therapy 18
Differentiation 18
Physician Product Ratings 18
Market Overview 21
Leading Products 22
Market History 22
Current Market Environment 23
Access/Formulary Changes 23
Therapeutic Substitution 23
Impact on Promotion 23
Future Market Environment 24
Increased Prevalence 24
Increased Awareness 24
Introduction of Novel Drugs 24
Tighter Managed Care Coverage 24
Reduction in DTC Spending 24
Increased FDA Scrutiny 24
Launch of New Drug Classes 24
Prospects for Future Therapies 25
Product Profiles
Ambien/Ambien CR 27
U.S. Perspective 27
Worldwide Perspective 28
AVOS Physician Panel Discussions 28
Zolpidem/zolpidem CR 29
U.S. Perspective 29
Worldwide Perspective 30
AVOS Physician Panel Discussions 30
Sonata/zaleplon 31
U.S. Perspective 31
Worldwide Perspective 32
AVOS Physician Panel Discussions 32
Lunesta/eszopiclone 33
U.S. Perspective 33
Worldwide Perspective 34
AVOS Physician Panel Discussions 34
Rozerem 35
U.S. Perspective 35
Worldwide Perspective 36
AVOS Physician Panel Discussions 36
Restoril/temazepam 37
U.S. Perspective 37
Worldwide Perspective 38
AVOS Physician Panel Discussions 38
Indiplon 39
U.S. Perspective 39
Worldwide Perspective 40
Silenor 41
U.S. Perspective 41
Worldwide Perspective 42
Eplivanserin/Volinanserin 43
U.S. Perspective 43
Worldwide Perspective 44
ORG 50081 45
U.S. Perspective 45
Worldwide Perspective 46
Almorexant 47
U.S. Perspective 47
Worldwide Perspective 48
Drugs in Development 49
R&D Overview 49
Non-Benzodiazepine GABA-A Agonists 49
Serotonin Therapies 49
Orexin Antagonists 49
Histamine Antagonists 49
Melatonin Receptor Agonists 49
Assessment of R&D Success Rates 50
Products in the Pipeline 51
Phase III (nine agents) 51
Phase II (10 agents) 52
Cover

Production date: January 2008

Order

Print Copy - $5,000

Single Site license PDF - $7,000

Global License PDF - $9,995

Contact Information:

If you wish to see sample pages or to learn more about AVOS Therapeutic Market Reports, contact Mike Goodman
919-475-9695
reports@avoslifesciences.com